Abstract

BackgroundLiver X receptor (LXR) α and LXR β (NR1H3 and NR1H2) are oxysterol-activated nuclear receptors involved in the control of major metabolic pathways such as cholesterol homeostasis, lipogenesis, inflammation and innate immunity. Synthetic LXR agonists are currently under development and could find applications in various fields such as cardiovascular diseases, cancer, diabetes and neurodegenerative diseases. The clinical development of LXR agonists requires the identification of biological markers for pharmacodynamic studies. In this context, monocytes represent an attractive target to monitor LXR activation. They are easily accessible cells present in peripheral blood; they express LXR α and β and respond to LXR agonist stimulation in vitro. The aim of our study was to identify cell surface markers of LXR agonists on monocytes. For this, we focused on clusters of differentiation (CD) markers because they are well characterized and accessible cell surface molecules allowing easy immuno-phenotyping.Methodology/Principal FindingsBy using microarray analysis of monocytes treated or not with an LXR agonist in vitro, we selected three CD, i.e. CD82, CD226, CD244 for further analysis by real time PCR and flow cytometry. The three CD were up-regulated by LXR agonist treatment in vitro in a time- and dose- dependent manner and this induction was LXR specific as assessed by a SiRNA or LXR antagonist strategy. By using flow cytometry, we could demonstrate that the expression of these molecules at the cell surface of monocytes was significantly increased after LXR agonist treatment.Conclusions/SignificanceWe have identified three new cell surface markers that could be useful to monitor LXR activation. Future studies will be required to confirm the biological and diagnostic significance of the markers.

Highlights

  • Liver X receptor (LXR) a and LXR b (NR1H3 and NR1H2 respectively) are two nuclear receptors activated by oxysterols

  • Amongst the clusters of differentiation (CD) markers, 3 genes were highly induced by LXR agonist treatment: CD82, CD226 (DNAX accessory molecule 1) and CD244. mRNA levels of these genes were induced by at least 2.5 fold in the monocytes of two different healthy donors in T0901317 conditions as compared to untreated monocytes

  • We wanted to assess whether increased mRNA levels in monocytes after T0901317 treatment reflect the response of differentiated macrophages or foam cells to LXR agonist stimulation

Read more

Summary

Introduction

Liver X receptor (LXR) a and LXR b (NR1H3 and NR1H2 respectively) are two nuclear receptors activated by oxysterols. Selective depletion of LXR a in the liver does not affect the atheroprotective potential of LXR agonists [19] These data suggest that macrophages/ foam cells are the primary targets for LXR agonists in the context of atherosclerosis prevention or treatment. Liver X receptor (LXR) a and LXR b (NR1H3 and NR1H2) are oxysterol-activated nuclear receptors involved in the control of major metabolic pathways such as cholesterol homeostasis, lipogenesis, inflammation and innate immunity. The clinical development of LXR agonists requires the identification of biological markers for pharmacodynamic studies In this context, monocytes represent an attractive target to monitor LXR activation. Monocytes represent an attractive target to monitor LXR activation They are accessible cells present in peripheral blood; they express LXR a and b and respond to LXR agonist stimulation in vitro. We focused on clusters of differentiation (CD) markers because they are well characterized and accessible cell surface molecules allowing easy immuno-phenotyping

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call